NOMAD POWER SOLUTIONS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NOMAD POWER SOLUTIONS, INC. (NMAD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $82.18 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-05-14
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $82.18K, a 17.61% decline year-over-year.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $328.51K, a 321.29% increase year-over-year.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $692.08K, a 547.85% increase year-over-year.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $268.00K, a 105.06% increase year-over-year.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.39M, a 231.80% increase from fiscal 2024.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $418.42K, a 45.88% decline from fiscal 2023.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $773.20K, a 49.99% decline from fiscal 2022.
- NOMAD POWER SOLUTIONS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.55M, a 40.51% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-03-31 | $82.18K 10-Q · filed 2026-05-14 | $410.68K derived: sum of 2 quarters · filed 2026-05-14 | $1.10M derived: sum of 3 quarters · filed 2026-05-14 | $1.37M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | $328.51K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.02M derived: sum of 2 quarters · filed 2026-03-31 | $1.29M derived: sum of 3 quarters · filed 2026-03-31 | $1.39M 10-K · filed 2026-03-31 |
| 2025-09-30 | $692.08K 10-Q · filed 2025-11-12 | $960.08K derived: sum of 2 quarters · filed 2025-11-12 | $1.06M 10-Q · filed 2025-11-12 | $1.14M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-06-30 | $268.00K 10-Q · filed 2025-08-07 | $367.74K 10-Q · filed 2025-08-07 | $445.71K derived: sum of 3 quarters · filed 2026-05-14 | $552.54K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-03-31 | $99.74K 10-Q · filed 2026-05-14 | $177.72K derived: sum of 2 quarters · filed 2026-05-14 | $284.54K derived: sum of 3 quarters · filed 2026-05-14 | $415.23K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $77.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $184.80K derived: sum of 2 quarters · filed 2026-03-31 | $315.50K derived: sum of 3 quarters · filed 2026-03-31 | $418.42K 10-K · filed 2026-03-31 |
| 2024-09-30 | $106.83K 10-Q · filed 2025-11-12 | $237.52K derived: sum of 2 quarters · filed 2025-11-12 | $340.44K 10-Q · filed 2025-11-12 | $444.50K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $130.69K 10-Q · filed 2025-08-07 | $233.62K 10-Q · filed 2025-08-07 | $337.68K derived: sum of 3 quarters · filed 2025-08-07 | $449.78K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $102.93K 10-Q · filed 2025-05-12 | $206.98K derived: sum of 2 quarters · filed 2025-05-12 | $319.09K derived: sum of 3 quarters · filed 2025-05-12 | $599.15K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $104.06K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $216.16K derived: sum of 2 quarters · filed 2025-03-24 | $496.22K derived: sum of 3 quarters · filed 2025-03-24 | $773.20K 10-K · filed 2025-03-24 |
| 2023-09-30 | $112.11K 10-Q · filed 2024-11-12 | $392.17K derived: sum of 2 quarters · filed 2024-11-12 | $669.15K 10-Q · filed 2024-11-12 | $1.05M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $280.06K 10-Q · filed 2024-08-08 | $557.04K 10-Q · filed 2024-08-08 | $942.43K derived: sum of 3 quarters · filed 2024-08-08 | $1.34M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $276.98K 10-Q · filed 2024-05-09 | $662.37K derived: sum of 2 quarters · filed 2024-05-09 | $1.06M derived: sum of 3 quarters · filed 2024-05-09 | $1.48M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $385.39K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $782.27K derived: sum of 2 quarters · filed 2024-03-19 | $1.21M derived: sum of 3 quarters · filed 2024-03-19 | $1.55M 10-K · filed 2024-03-19 |
| 2022-09-30 | $396.88K 10-Q · filed 2023-11-09 | $820.98K derived: sum of 2 quarters · filed 2023-11-09 | $1.16M 10-Q · filed 2023-11-09 | $1.91M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $424.09K 10-Q · filed 2023-08-09 | $763.77K 10-Q · filed 2023-08-09 | $1.51M derived: sum of 3 quarters · filed 2023-08-09 | $1.86M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $339.67K 10-Q · filed 2023-05-10 | $1.08M derived: sum of 2 quarters · filed 2023-05-10 | $1.43M derived: sum of 3 quarters · filed 2023-05-10 | $2.28M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $744.86K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.09M derived: sum of 2 quarters · filed 2023-03-29 | $1.94M derived: sum of 3 quarters · filed 2023-03-29 | $2.60M 10-K · filed 2023-03-29 |
| 2021-09-30 | $347.22K 10-Q · filed 2022-11-08 | $1.20M derived: sum of 2 quarters · filed 2022-11-08 | $1.85M 10-Q · filed 2022-11-08 | $1.94M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $850.80K 10-Q · filed 2022-08-10 | $1.51M 10-Q · filed 2022-08-10 | $1.59M derived: sum of 3 quarters · filed 2022-08-10 | $2.66M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $656.03K 10-Q · filed 2022-05-11 | $742.63K derived: sum of 2 quarters · filed 2022-05-11 | $1.81M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $86.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.15M derived: sum of 2 quarters · filed 2022-03-21 | $1.15M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $1.06M 10-Q · filed 2021-11-10 | $1.06M 10-Q · filed 2021-11-10 | ||
| 2019-12-31 | $748.65K 10-K · filed 2021-03-26 | |||
| 2019-09-30 | $439.05K 10-Q · filed 2020-11-10 | $735.72K derived: sum of 2 quarters · filed 2020-11-10 | $748.65K derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $296.67K 10-Q · filed 2020-11-10 | $309.60K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $12.94K 10-Q · filed 2020-11-10 | |||
| 2018-09-30 | $772.39K 10-Q · filed 2019-11-08 | |||
| 2016-09-30 | $145.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $324.50K derived: sum of 2 quarters · filed 2016-11-04 | $294.13K 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $178.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $148.32K 10-Q · filed 2016-08-10 | ||
| 2016-03-31 | -$30.37K 10-Q · filed 2016-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |